Table 4: Baseline characteristics after propensity score matching

	NC-ABL (N=43)	C-ABL (N=43)	P-value
Male sex – no. (%)	37 (86.0)	33 (76.7)	0.268
Age – mean ± SD	60 ± 14	61 ± 12	0.525
BMI – mean ± SD	27 ± 4	27 ± 4	0.810
HTN – no. (%)	28 (65.8)	27 (62.8)	0.822
DL – no. (%)	23 (53.5)	23 (53.5)	1.000
DM2 – no. (%)	8 (18.6)	5 (11.6)	0.366
Previous smoking – no. (%)	13 (30.2)	17 (39.5)	0.365
Previous AMI – no. (%)	17 (39.5)	16 (37.2)	0.825
Previous CABG – no. (%)	8 (18.6)	10 (23.3)	0.596
Atrial fibrillation – no. (%)	10 (23.3)	2 (4.6)	0.026
COPD – no. (%)	11 (25.6)	7 (16.3)	0.289
CKD – no. (%)	15 (34.9)	11 (25.6)	0.348
Beta-blocker – no. (%)	42 (97.7)	43 (100)	0.811
ACEI or ARB – no. (%)	39 (90.1)	41 (95.3)	0.586
MRA – no. (%)	31 (72.1)	27 (62.8)	0.357
Amiodarone – no. (%)	33 (76.7)	37 (86.0)	0.268
Other AAD – no. (%)	6 (14.0)	3 (7.0)	0.291
TV-ICD – no. (%)	41 (95.3)	42 (97.7)	0.816
S-ICD – no. (%)	2 (4.6)	1 (2.3)	0.831
LVEF (%) – mean ± SD	33 ± 12	34 ± 11	0.789
Non ischemic etiology – no. (%)	27 (62.8)	27 (62.8)	1.000
Previous Ablation – no. (%)	31 (72.1)	31 (72.1)	1.000
Complications – no. (%)	4 (9.3)	6 (12.9)	0.501
Pericardial effusion – no. (%)	1 (2.3)	4 (14.0)	0.167
Right ventricle puncture – no. (%)	0 (0)	2 (4.6)	0.152
Vascular complication – no. (%)	1 (2.3)	0 (0)	0.315
Complete heart block – no. (%)	2 (4.6)	1 (2.3)	0.557

AAD= antiarrhythmic drug; ACEI=angiotensin-converting-enzyme inhibitor; AMI=acute myocardial infarction; ARB=angiotensin II receptor blocker; BMI=body-mass index; CABG=coronary artery bypass grafting; CKD=chronic kidney disease; DL=dyslipidemia; DM2=diabetes mellitus type 2; END-ABL=endocardial ablation; EPI-ABL=epicardial ablation; HTN=systemic hypertension; LVEF=left ventricle ejection fraction; MRA= mineralocorticoid receptor antagonist; S-ICD= subcutaneous implantable cardioverter-defibrillator; TV-ICD=transvenous implantable cardioverter-defibrillator;